Related Experiment Videos
Bipolar II disorder: an overview of recent developments
George Hadjipavlou1, Hiram Mok, Lakshmi N Yatham
1Department of Psychiatry, University of British Columbia, Vancouver.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
|February 1, 2005
Summary
Bipolar II disorder (BD II) is likely more common than previously thought, and early detection is improving. Current treatment recommendations for BD II are limited, with lithium or lamotrigine suggested as initial options.
Area of Science:
- Psychiatry
- Clinical Psychology
- Neuroscience
Background:
- Bipolar II disorder (BD II) diagnosis and treatment require updated clinical guidance.
- Recent research offers new insights into BD II epidemiology and clinical progression.
Purpose of the Study:
- To review recent advancements in the epidemiology, clinical course, diagnosis, and treatment of Bipolar II disorder.
- To provide clinicians with an updated overview of BD II management.
Main Methods:
- A comprehensive literature search was conducted using Pubmed.
- The search focused on articles published between January 1, 1994, and August 31, 2004.
- Articles relevant to BD II epidemiology, course, diagnosis, and management were selected.
Main Results:
- The prevalence of BD II may be underestimated in current literature.
- Systematic screening and probing for specific symptoms enhance early and accurate BD II detection.
- High-quality data for guiding BD II treatment remains scarce.
Conclusions:
- Progress has been made in understanding BD II diagnosis and treatment.
- Lithium and lamotrigine are suggested as potential first-line treatments for BD II, based on limited evidence.
- Further large-scale, well-designed studies are necessary to establish robust evidence-based treatment guidelines for BD II.